Toric Trifocal IOL Treatment With High Astigmatism and Hyperopia vs SMILE Enhancement After Trifocal IOL Treatment
Launched by EYE HOSPITAL PRISTINA KOSOVO · Jul 9, 2020
Trial Information
Current as of June 20, 2025
Completed
Keywords
ClinConnect Summary
The current state of the art for the correction of aphakia and presbyopia after lens extraction and refractive lensectomy is the implantation of multifocal intraocular lenses (IOL). In this study, the trifocal IOL types AT LISA TRI 839MP and AT LISA TRI TORIC 939MP (Carl Zeiss Meditec, Germany) were assessed.
In this prospective non-randomized study patients with spherical hypermetropia of \>4 D in combination with high astigmatism of \>3.0 D were treated. The first group of 40 eyes of 20 patients underwent refractive lensectomy, followed by implantation of the diffractive trifocal IOL typ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. High spherical hypermetropia
- • 2. Astigmatismus \>2 D or higher
- • 3. Amblyopia
- • 4. Strabismus (accomodative esotropia)
- Exclusion Criteria:
- • 1. Glaucoma
- • 2. Retinal detachment
- • 3. Corneal disease
- • 4. Macular degeneration
- • 5. Advanced Retinopathy
About Eye Hospital Pristina Kosovo
Eye Hospital Pristina, located in Kosovo, is a leading clinical research institution dedicated to advancing ophthalmic care through rigorous clinical trials. Committed to improving patient outcomes, the hospital specializes in innovative treatments and technologies in eye health. With a multidisciplinary team of experienced ophthalmologists and researchers, Eye Hospital Pristina actively participates in collaborative studies aimed at enhancing the understanding and management of various eye conditions. The institution prioritizes patient safety and ethical standards, ensuring the highest quality of care and adherence to international research protocols.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pristina, , Kosovo
Patients applied
Trial Officials
Faruk Semiz, Dr.
Principal Investigator
Principal Doctor
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials